Canada Health News API

{
    "totalArticles": 285012,
    "articles": [
        {
            "id": "964101bd0fd874eff2fb33cdc8d1e93a",
            "title": "Beyond the blog: Meet Dal's 2026 OpenThinkers",
            "description": "A reimagined OpenThink cohort moves beyond blogging, testing podcasts and social media to broaden impact, connect with new audiences, and amplify how Dal research informs public dialogue and policy.",
            "content": "Heard of OpenThink? Sure, but not like this.\nFifteen PhD students from nine faculties across Dalhousie are the newest members of the university’s annual OpenThink program, designed to help them share their research beyond academia to influence public... [5579 chars]",
            "url": "https://www.dal.ca/news/2026/06/25/openthink-2026-dalhousie.html",
            "image": "https://cdn.dal.ca/news/2026/06/25/openthink-2026-dalhousie/_jcr_content/image.adaptive.full.high.jpg/1782391423575.jpg",
            "publishedAt": "2026-06-25T12:49:29Z",
            "lang": "en",
            "source": {
                "id": "a43da04239aa76d14c176a65ad804a6a",
                "name": "Dalhousie University",
                "url": "https://www.dal.ca"
            }
        },
        {
            "id": "0fca23f7789d231acb95d60fddd43008",
            "title": "Hypertension : cette boisson appréciée des enfants augmente les risques",
            "description": "Les enfants qui consomment des boissons sucrées ont plus de risques d’avoir une pression artérielle élevée à l’âge adulte.",
            "content": "Une preuve de plus qu’il n’est vraiment pas bon de donner des boissons sucrées aux enfants. Des chercheurs de la Harvard T.H. Chan School of Public Health ont découvert que les personnes ayant consommé beaucoup de sodas, de boissons énergisantes et d... [1921 chars]",
            "url": "https://www.pourquoidocteur.fr/Articles/Question-d-actu/55193-Hypertension-boisson-appreciee-enfance-augmente-risques",
            "image": "https://www.pourquoidocteur.fr/media/article/istock-931078842-1782379887.jpg",
            "publishedAt": "2026-06-25T12:45:00Z",
            "lang": "fr",
            "source": {
                "id": "fad2b3a2a712b01baad87009bb046440",
                "name": "Pourquoi Docteur",
                "url": "https://www.pourquoidocteur.fr"
            }
        },
        {
            "id": "d525acd2d6541974b35a548d6ff7fd1b",
            "title": "MUHC launches world’s first radioligand therapy trial for HER2-positive cancers",
            "description": "The MUHC is the first in the world to launch a Phase I trial of a novel radioligand therapy for HER2-positive cancers, including some breast cancers.",
            "content": "The MUHC is the first site in the world to launch a first-in-human Phase I clinical trial evaluating a novel radioligand therapy for HER2-positive cancers, including certain types of breast cancer.\nA highly innovative therapeutic approach for HER2-po... [4104 chars]",
            "url": "https://muhc.ca/news-and-patient-stories/news/muhc-launches-worlds-first-radioligand-therapy-trial-her2-positive",
            "image": "https://muhc.ca/sites/default/files/2026-06/radioligand_image_web-intranet.png",
            "publishedAt": "2026-06-25T12:35:20Z",
            "lang": "en",
            "source": {
                "id": "cae2e78c17155f4ee547fe4a74b191b4",
                "name": "McGill University Health Centre",
                "url": "https://muhc.ca"
            }
        }
    ]
}